Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights
Aura Biosciences, Inc. (AURA)
Company Research
Source: GlobeNewswire
Positive Phase 2 End of Study Data with Bel-sar in Early-Stage Choroidal Melanoma; Ongoing Phase 3 CoMpass Trial Recently Received Authorization to Start Enrolling Patients in Europe Multiple Clinical Complete Responses Observed with Single Low Dose of Bel-sar in Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer (NMIBC); Phase 1 Expansion Preparation in Progress Strong Cash Position Expected to Support Operations into 2H 2026 BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the third quarter ended September 30, 2024, and provided recent business highlights. “This is a transformative time for our Company, as we presented the first positive data in NMIBC, which we believe provides clinical evidence of the potential of bel-sar in solid tumors beyond the eye,” said Elisabet d
Show less
Read more
Impact Snapshot
Event Time:
AURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AURA alerts
High impacting Aura Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
AURA
News
- Aura Biosciences, Inc. (NASDAQ: AURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.MarketBeat
- Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value [Seeking Alpha]Seeking Alpha
- Aura Biosciences, Inc. (NASDAQ: AURA) had its "buy" rating re-affirmed by analysts at Cowen Inc.MarketBeat
- Aura Biosciences, Inc. (NASDAQ: AURA) had its price target raised by analysts at Scotiabank from $20.00 to $23.00. They now have a "sector outperform" rating on the stock.MarketBeat
- Aura Biosciences, Inc. (NASDAQ: AURA) had its price target raised by analysts at BTIG Research from $21.00 to $24.00. They now have a "buy" rating on the stock.MarketBeat
AURA
Earnings
- 11/12/24 - Beat
AURA
Sec Filings
- 11/18/24 - Form 4
- 11/18/24 - Form 144
- 11/14/24 - Form SC
- AURA's page on the SEC website